NovoCure (NVCR) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
NovoCure insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 14 sold $3.3M of NVCR stock on the open market.
Get emailed when insiders cluster-buy stocks like NVCR
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NVCR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $940K | 8 |
| Q1 2026 | — | 0 | $2.3M | 17 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 NovoCure Ltd insiders reported open-market purchases totaling $0, while 14 insiders reported sales totaling $3.3M. 0 of 25 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 5SEC | Frank X LeonardCEO | Sell | 34,273459,520 held (−7%) | $17.93 | $615K | -18.7% | — |
| Jun 3SEC | Jeryl L HillemanDirector | Sell | 2,94513,861 held (−18%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | Timothy J ScannellDirector | Sell | 2,94514,288 held (−17%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | Gabriel LeungDirector | Sell | 2,94589,499 held (−3%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | David HungDirector | Sell | 2,94520,465 held (−13%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | Kristin StaffordDirector | Sell | 2,94511,324 held (−21%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | W Anthony VernonDirector | Sell | 2,945197,657 held (−1%) | $15.77 | $46K | -7.5% | — |
| Jun 3SEC | Allyson J OceanDirector | Sell | 2,94511,324 held (−21%) | $15.77 | $46K | -7.5% | — |
| Mar 5SEC | William F DoyleChair | Sell | 50,557349,727 held (−13%) | $12.79 | $647K | +14.0% | — |
| Mar 5SEC | Mukund ParavasthuCOO | Sell | 43,24672,832 held (−37%) | $13.77 | $595K | +5.9% | — |
| Mar 5SEC | William F DoyleChair | Sell | 21,330328,397 held (−6%) | $13.43 | $286K | +8.6% | — |
| Mar 5SEC | Uri WeinbergChf Medical And Innovation Ofr | Sell | 6,412267,190 held (−2%) | $13.31 | $85K | +9.5% | — |
| Mar 5SEC | Christoph BrackmannCFO | Sell | 6,412182,842 held (−3%) | $13.31 | $85K | +9.5% | — |
| Mar 5SEC | Frank X LeonardCEO | Sell | 5,607493,793 held (−1%) | $13.31 | $75K | +9.5% | — |
| Mar 5SEC | Mukund ParavasthuCOO | Sell | 5,377116,078 held (−4%) | $13.31 | $72K | +9.5% | — |
| Mar 5SEC | Nicolas LeupinFormer Chief Medical Officer | Sell | 1,100102,979 held (−1%) | $13.31 | $15K | +9.5% | — |
| Mar 5SEC | Michal Nath PuriChief Human Resources Officer | Sell | 1,100201,322 held (−1%) | $13.31 | $15K | +9.5% | — |
| Mar 3SEC | Frank X LeonardCEO | Sell | 9,734338,011 held (−3%) | $13.66 | $133K | +6.7% | — |
| Mar 3SEC | Uri WeinbergChf Medical And Innovation Ofr | Sell | 7,461213,757 held (−3%) | $13.84 | $103K | +5.3% | — |
| Mar 3SEC | Frank X LeonardCEO | Sell | 7,232349,400 held (−2%) | $13.49 | $98K | +8.1% | — |
| Mar 3SEC | Uri WeinbergChf Medical And Innovation Ofr | Sell | 3,272223,477 held (−1%) | $13.33 | $44K | +9.4% | — |
| Mar 3SEC | Mukund ParavasthuCOO | Sell | 1,55576,751 held (−2%) | $13.66 | $21K | +6.7% | — |
| Mar 3SEC | Michal Nath PuriChief Human Resources Officer | Sell | 1,441162,322 held (−1%) | $13.66 | $20K | +6.7% | — |
| Mar 3SEC | Nicolas LeupinFormer Chief Medical Officer | Sell | 1,029104,079 held (−1%) | $13.66 | $14K | +6.7% | — |
| Mar 3SEC | Mukund ParavasthuCOO | Sell | 40876,343 held (−1%) | $13.49 | $6K | +8.1% | — |
Insiders at NovoCure Ltd
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| William F DoyleChair | — | $933K | Mar 5, 2026 | — |
| Frank X LeonardCEO | — | $920K | Jun 5, 2026 | — |
| Mukund ParavasthuCOO | — | $694K | Mar 5, 2026 | — |
| Uri WeinbergChf Medical And Innovation Ofr | — | $232K | Mar 5, 2026 | — |
| Christoph BrackmannCFO | — | $85K | Mar 5, 2026 | — |
| Jeryl L HillemanDirector | — | $46K | Jun 3, 2026 | — |
| Timothy J ScannellDirector | — | $46K | Jun 3, 2026 | — |
| Gabriel LeungDirector | — | $46K | Jun 3, 2026 | — |
| David HungDirector | — | $46K | Jun 3, 2026 | — |
| Kristin StaffordDirector | — | $46K | Jun 3, 2026 | — |
| W Anthony VernonDirector | — | $46K | Jun 3, 2026 | — |
| Allyson J OceanDirector | — | $46K | Jun 3, 2026 | — |
| Michal Nath PuriChief Human Resources Officer | — | $34K | Mar 5, 2026 | — |
| Nicolas LeupinFormer Chief Medical Officer | — | $29K | Mar 5, 2026 | — |
NVCR stock: common questions
Are NovoCure Ltd insiders buying NVCR stock?
In the past 12 months, 0 insiders reported open-market purchases of NVCR worth $0.
Are NovoCure Ltd insiders selling NVCR stock?
14 insiders reported sales worth $3.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NVCR's 52-week range?
Over the past year NVCR has traded between $10.03 and $19.99. It last closed at $14.58 on Oct 9, 2026.